Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study of Atezolizumab (an Engineered Anti-Programmed Death-Ligand 1 [PDL1] Antibody) to Evaluate Safety, Tolerability and Pharmacokinetics in Participants With Locally Advanced or Metastatic Solid Tumors

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01375842
Recruitment Status : Completed
First Posted : June 17, 2011
Last Update Posted : December 11, 2018
Sponsor:
Information provided by (Responsible Party):
Genentech, Inc.

No Study Results Posted on ClinicalTrials.gov for this Study
  Recruitment Status : Completed
  Actual Primary Completion Date : September 30, 2018
  Actual Study Completion Date : September 30, 2018
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):